

*Science is simply  
common sense  
at its best . . . T. A. Huxley*

*Introducing the state-of-the-art technology  
in the detection of Ag-Ab reaction*

## **StrAviGen™ Super Sensitive**

*More signal per binding event!*

- **Offers up to 50 times more sensitivity.**
- **Minimizes the need for frozen tissue.**
- **75% reduction in primary antibody incubation time.**
- **10-50 times higher titer with primary antibodies.**

**and more!**

Available from BioGenex, *the common sense people.*

The StrAviGen Super Sensitive System is available in Universal Kits,  
Concentrated Kits and Complete Kits with Ready-to-Use Antibodies.

*Our commitment to you is complete satisfaction!*



**BioGenex Laboratories**

4600 Norris Canyon Rd., Suite 200, San Ramon, CA 94583 • (415) 275-0550 • FAX (415) 275-0580

Toll Free (800) 421-4149

As of 1990 6 issues  
per volume instead of 4

# Regional Cancer Treatment

## From the Contents of Volume 2 1989

### Managing Editors:

K. R. Aigner, Trostberg;  
E. T. Kremenz, New Orleans,  
LA; F. O. Stephens, Sydney  
in cooperation with an inter-  
national editorial board from  
the following fields:

Head-Neck; Immunology;  
Medical Oncology; Neuro-  
surgery; Pain treatment;  
Pathology; Pediatrics; Pharma-  
cology; Radiology; Surgery;  
Urology

coloured illustrations

### P. V. Danenberg, A. R. Bapat:

Thymidylate synthases isolated from human colon tumors have varied affinity towards 5-fluoro-2'-deoxyuridylate

### M. Markman, D. Kelsen:

Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma

### F. O. Stephens:

Seven principles of induction chemotherapy

### L. Weiss:

Metastatic inefficiency and regional therapy for liver metastases from colorectal carcinoma

### H. Müller, K.R. Aigner, H. Walther:

Isolated pelvic perfusion for nonresectable pelvic tumors. A pilot study

### Y. Z. Patt, C. Charnsangavej, A. Boddie, K. Cleary, C. H. Carrasco, M. Soski, L. Claghorn, M. Lambert, L. Lamki, G. Mavligit:

Treatment of hepatocellular carcinoma with hepatic arterial fluoxuridine, doxorubicin, and mitomycin (FUDRAM) with or without hepatic artery embolization: factors associated with longer survival

SUBSCRIPTION/SAMPLE COPY  
ORDER FORM

## Regional Cancer Treatment

ISSN 0935-0411 Title No. 465

Please return to:  
Springer-Verlag New York, Inc.  
Attn: E. Teatsorth  
175 Fifth Avenue  
New York, NY 10010

Springer-Verlag

New York Berlin Heidelberg Vienna London Paris Tokyo Hong Kong

Please enter my subscription to Volume 3, (6 issues) 1990: \$153.00\*

Please send me a FREE sample copy

Check enclosed (made payable to Springer-Verlag New York, Inc.)

Charge my

AmEx

VISA

MC

9/89 H661

Card No. \_\_\_\_\_ Exp. Date \_\_\_\_\_

Signature \_\_\_\_\_

Name \_\_\_\_\_

Address \_\_\_\_\_

City/State/Zip \_\_\_\_\_

Subscriptions are entered with prepayment only and filled as issues are published.

\*Prices include postage and handling.

Springer





# VECTOR

## Labels

**Alkaline Phosphatase**  
**Peroxidase**  
 **$\beta$ -Galactosidase**  
**Glucose Oxidase**  
**Phycoerythrin**  
**Fluorescein**  
**Texas Red**  
**Rhodamine**  
**AMCA (blue fluorescence)**  
**Biotin**

## Conjugates

**Antibodies**  
**Avidin**  
**Streptavidin**  
**Lectins**

Whether your research involves immunocytochemistry, flow cytometry, transfer blotting, enzyme immunoassays, or fluorescent microscopy, reagents from Vector can optimize your detection system. For a complete catalog or specific protocols, please phone or write:

**VECTOR LABORATORIES, INC.,**  
30 Ingold Road, Burlingame, CA 94010. (415) 697-3600.  
**VECTOR LABORATORIES, LTD.,**  
16 Wulfric Square, Bretton, Peterborough  
PE3 8RF U.K. (0733) 265530.



© 1989 Vector Laboratories, Inc.

# OFFERS:

# ANNOUNCING

The First Meeting on

## THE MOLECULAR BASIS OF HUMAN CANCER

JUNE 13-16, 1990

HOOD COLLEGE  
FREDERICK, MARYLAND

Organizers: **R. Dalla Favera** **N. Rosen**  
**M. Israel** **G. Vande Woude**  
**I. Kirsch** **B. Vogelstein**  
**D. Longo**

The meeting will provide a forum for the clinically oriented investigator to participate in a comprehensive exchange of research directed at the molecular biology of human cancers. It will focus on the identification of specific genetic lesions associated with human cancers, the elucidation of their role in pathogenesis and progression, and the potential diagnostic and therapeutic implications of these discoveries. The meeting will be structured to provide a comprehensive overview by organ system as well as novel approaches of general significance. Selected abstracts will be presented by the individual investigator.

For further information on registration and abstract submittal, please contact:

**Margaret L. Fanning**  
Conference Coordinator  
P.O. Box 249  
Libertytown, Maryland 21762  
301 898-9266 FAX 301 898-9173

Sponsored by the Foundation for Advanced Cancer Studies, Inc.

Copies of articles from this publication are now available from the UMI Article Clearinghouse.

For more information about the Clearinghouse, please fill out and mail back the coupon below.

UMI Article  
Clearinghouse

Yes! I would like to know more about UMI Article Clearinghouse. I am interested in electronic ordering through the following system(s):

- DIALOG/Dialorder  ITT Dialcom  
 OnTyme  OCLC ILL Subsystem  
 Other (please specify) \_\_\_\_\_  
 I am interested in sending my order by mail.  
 Please send me your current catalog and user instructions for the system(s) I checked above.

Name \_\_\_\_\_

Title \_\_\_\_\_

Institution/Company \_\_\_\_\_

Department \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone (\_\_\_\_\_) \_\_\_\_\_

Mail to: University Microfilms International  
300 North Zeeb Road, Box 91 Ann Arbor, MI 48106

## "YES, THERE IS LIFE AFTER BREAST CANCER. AND THAT'S THE WHOLE POINT."

—Ann Jillian



A lot of women are so afraid of breast cancer they don't want to hear about it.

And that's what frightens me.

Because those women won't practice breast self-examination regularly.

Those women, particularly those over 35, won't ask their doctor about a mammogram.

Yet that's what's required for breast cancer to be detected early. When the cure rate is 90%. And when there's a good chance it won't involve the loss of a breast.

But no matter what it involves, take it from someone who's been through it all.

Life is just too wonderful to give up on. And, as I found out, you don't have

to give up on any of it. Not work, not play, not even romance.

Oh, there is one thing, though.

You do have to give up being afraid to take care of yourself.

 **AMERICAN CANCER SOCIETY®**  
Get a checkup. Life is worth it.

KEEP UP WITH THE LATEST DEVELOPMENTS  
IN  
**Cancer Research**

THE OFFICIAL JOURNAL OF  
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

**Subscribe to *Cancer Research***—the leading citation source of original studies in cancer research and cancer-related biomedical science. Issued semimonthly, *Cancer Research* publishes over 8,000 pages per year that keep you abreast of the most significant and timely findings in your field through the following regular features:

- **The most up-to-date articles** in basic research and clinical and epidemiological investigations by authors from the United States and more than 20 countries
- **Perspectives in Cancer Research**, in which leading investigators explore contemporary and at times controversial topics
- **Supplemental issues** developed from symposia on relevant subjects—the January 1990 Supplement features the *Second Conference on Radioimmunodetection and Radioimmunotherapy of Cancer*.
- **Proceedings of the American Association for Cancer Research**, a special annual issue that offers stimulating new research ideas in abstract form

ORDER THE MOST HIGHLY CITED JOURNAL IN ITS FIELD  
TODAY

-----  
 Yes, I want to keep up with the latest developments in *Cancer Research*. Enter my one-year subscription.

1990 Subscription Rates:     Individual, \$265     Institutional, \$295

Add \$60 for delivery outside the U.S. Subscriptions payable in advance (in US currency or equivalent) to:

WAVERLY PRESS, INC.  
c/o Cancer Research  
428 East Preston St.  
Baltimore, MD 21202

Allow 8 weeks for receipt of first issue.

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_







INTRODUCING

The next important name in Cancer Care

CIBA-GEIGY

*Innovators in Cancer Research*

